Bob Odenkirk recently gave his take on the upcoming end of The Late Show with Stephen Colbert. While discussing the cancellation during a Comic-Con interview, Odenkirk compared Colbert’s future ...

Our client is looking for a Data Engineer/Data Scientist fully in Office role based in JHB Key Requirements 5+ years’ experience overall. BSc/ BTech/ [URL Removed] Python – Pandas, NumPy, Scikit-learn ...

Our client is looking for a Data Engineer/Data Scientist fully in Office role based in JHB Key Requirements 5+ years’ experience overall. BSc/ BTech/ [URL Removed] Python – Pandas, NumPy, Scikit-learn ...

When a young boy thinks his dad looks like Dwayne Johnson, the TikTok post finds its way to The Rock and hilarity ensues.

Personal information about Columbia University students and applicants, including acceptance/rejection status, has been stolen, according to a review of data provided by an alleged hacker. The ...

Gov. Tina Kotek used outdated figures to contend earlier this month that Multnomah County’s voter-approved Preschool for All tax was placing an undue burden on high-income earners that was ...

XRP, ADA Lead Crypto Majors Slide, While Bitcoin Watchers Target Return to Highs in Q3 Fresh policy moves on stablecoins and bitcoin's long-term holder activity are signs for some traders to ...

Meta’s $14.3 billion investment in Scale AI, the leading player in the AI data industry, was a very strange deal indeed. Meta acquired 49% of the company in the deal announced last Thursday ...

Intel plans to lay off up to a fifth of its factory workers, an enormous cutback that will have a profound effect on one of the chipmaker’s core businesses.

Ali Ghodsi, CEO of Databricks, said people underestimate how difficult it is to fully automate tasks and take humans out of the loop.

KBRA releases research examining the differences between asset-backed securities (ABS) and commercial mortgage-backed securities (CMBS) for data center transactions, providing insight into how ...

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year ...